Redhill Biopharma reported $28.85M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adamis Pharmaceuticals ADMP:US 8.88M 8.89M
Cara Therapeutics CARA:US $ 46.72M 25.36M
Cronos Group Inc CRON:CN 789.54M 71.99M
Intra Cellular Therapies ITCI:US $ 77.24M 52.06M
Redhill Biopharma RDHL:US $ 28.85M 0.63M